menu
    • menu

    Company profile for OriCell Therapeutics

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth ov...
    Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OriCell TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    Third Floor, Building #1, 1227 Zhangheng Rd, Pudong District, Shanghai
    Telephone
    Telephone
    +8621-68868119
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.oricell.com/en/about/desc/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oricell Therapeutics Secures US$70M In Series C Funding
    Oricell Therapeutics Secures US$70M In Series C Funding

    12 Jan 2026

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/oricell-therapeutics-announces-us70m-initial-closing-of-series-c-financing-to-accelerate-global-development-of-solid-tumor-car-t-therapies-302659130.html

    PR NEWSWIRE BIO
    12 Jan 2026
    Share Share
    Oricell Announces FDA Clearance of IND Application for OriCAR-017
    Oricell Announces FDA Clearance of IND Application for OriCAR-017

    29 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oricell-announces-fda-clearance-of-ind-application-for-oricar-017-a-novel-gprc5d-targeted-car-t-cell-therapy-utilizing-the-companys-proprietary-platform-for-the-treatment-of-relapsedrefractory-multiple-myeloma-302046662.html

    PR NEWSWIRE
    29 Jan 2024
    Share Share
    Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving Way for Global Impact
    Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving Way for Global Impact

    10 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oricell-oricar-017-car-t-therapy-clears-ind-hurdle-paving-the-way-for-global-impact-301897862.html

    PR NEWSWIRE
    10 Aug 2023
    Share Share
    In push to expand its CAR-T therapies to US, Oricell raises additional $45M
    In push to expand its CAR-T therapies to US, Oricell raises additional $45M

    28 Feb 2023

    // Lei Lei Wu ENDPTS

    https://endpts.com/in-push-to-expand-its-car-t-therapies-to-us-china-biotech-oricell-raises-additional-45m/

    Lei Lei Wu ENDPTS
    28 Feb 2023
    Share Share
    Oricell Closes $45M Series B1 Financing to Expand Development of Key Products
    Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

    28 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oricell-closes-45m-series-b1-financing-to-expand-development-of-key-products-301756385.html

    PR NEWSWIRE
    28 Feb 2023
    Share Share
    Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017
    Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017

    30 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oricell-publishes-data-from-polaris-clinical-study-evaluating-oricar-017-in-the-treatment-of-rrmm-in-the-lancet-haematology-301734082.html

    PR NEWSWIRE
    30 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search